Revvity, Inc.

The provided transcript does not mention any current or planned new fundraising through debt or equity. Key points related to capital deployment are: - No explicit discussion of new debt or equity fundraising. - Focus on capital deployment includes share buybacks and acquisitive growth via M&A. - The company remains acquisitive, targeting tuck-in acquisitions to fill portfolio gaps. - Share buybacks are considered the biggest opportunity for capital return, with an opportunistic and aggressive approach. - No mention of issuing new equity or raising new debt as part of the capital strategy. - Divestiture proceeds (from China immunodiagnostics) are expected to be used mainly for share buybacks. - Cost efficiency initiatives and portfolio optimization are expected to aid financial performance without additional fundraising. In summary, no new debt or equity fundraising is indicated; focus is on M&A, divestitures, and share repurchases.

- The company continues to be acquisitive to fill any portfolio gaps but currently does not see any large-scale M&A opportunities; tuck-in acquisitions are possible. (Page 13) - The biggest capital deployment opportunity is share buybacks, and the company remains opportunistic and aggressive in this area. (Page 13) - There is no explicit mention of major capital expenditures, but operational efficiency initiatives are underway and expected to complete around mid-2026, which will significantly impact margins and cost structure. (Page 4, 12) - AI adoption internally, especially around software development and LLM rollouts, is a strategic focus area expected to improve productivity and efficiency at a low cost. (Page 8, 4) - Divestiture of the China immunodiagnostics business is a strategic move that will free up capital and management focus. Proceeds are expected to be used primarily for share buybacks. (Page 2, 13)

- 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% to 4%. - First quarter 2026 pro forma organic growth was strong at 6%, exceeding expectations. - Second quarter 2026 pro forma organic growth is guided at 2% to 3%, reflecting removal of the China immunodiagnostics business. - Life Science Solutions expected to grow low single digits in Q2; Diagnostics expected mid-to-high single digits growth. - Software business: mid-single digit organic growth expected for full year; Q2 software expected to decline around 20% due to tough comps but strong high teens growth anticipated in the second half of 2026. - Signs of improvement in pharma/biotech spending with low single-digit growth in Q1 2026, signaling a slow but positive recovery. - Reproductive health showing double-digit growth with strong instrument placements and reagent performance. - The divestiture of China immunodiagnostics expected to improve organic growth by ~100 bps and operating margins by ~30 bps going forward. - Cost productivity and operational efficiency initiatives expected to drive margin expansion, supporting future growth.

- 2026 Pro forma adjusted EPS guidance: $5.20 to $5.30, reflecting expected growth excluding China immunodiagnostics divestiture. - Operating margins expected to improve to approximately 28.4% in 2026, up 40 basis points from prior outlook, aided by cost efficiency programs and divestiture impact. - Cost efficiency initiatives to complete around mid-2026, driving further margin expansion realized especially in second half of 2026 and annualized benefits in 2027. - Additional catch-up in margins expected in first half of 2027, positioning for robust margin expansion moving forward. - Share buybacks seen as a key capital deployment to leverage proceeds from divestiture, supporting EPS growth. - Organic growth outlook for 2026: 3% to 4% (pro forma), with improving trends in underlying markets expected to continue. - Free cash flow conversion expected to improve post-divestiture, enhancing financial flexibility and growth prospects.

The provided transcript from the PDF does not contain specific details about the current or expected order book or pending orders. The discussion focuses mainly on: - Revenue growth guidance (3% to 4% organic growth for 2026 pro forma). - Divestiture of the China immunodiagnostics business and its impact on revenue and margins. - Incremental volume growth and seasonal pickup aiding margin improvements. - Software business trajectory and associated growth cadence. - Encouraging signs of modest improvement in pharma/biotech instruments and reagents. - No explicit mention or quantification of order book or pending orders. Therefore, no specific information about current or expected orderbook or pending orders is available in the provided pages.